The evolving role of oestrogen receptor beta in clinical breast cancer

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Controversy surrounds the potential clinical importance of oestrogen receptor (ER)beta in breast cancer, and three recent papers have sought to resolve this. In the present issue of Breast Cancer Research Novelli and colleagues explored the significance of ERbeta1 expression in 936 breast cancer patients, and they showed diverse relationships according to lymph node status. A second paper examined 442 breast cancers in which ERbeta1 was an independent predictor of recurrence, disease-free survival and overall survival. Finally a third paper showed that ERbeta2 was a powerful prognostic indicator in 757 breast cancers but this was dependent on cellular location, with nuclear ERbeta2 expression predicting good survival whilst cytoplasmic expression predicted worse outcome. These papers point to a clinical role for ERbeta in breast cancer and shall be discussed.

Original languageEnglish
Pages (from-to)111
JournalBreast Cancer Research
Issue number5
Publication statusPublished - 2008
Externally publishedYes


  • Adenocarcinoma
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Cell Nucleus
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Cytoplasm
  • Disease-Free Survival
  • Estrogen Receptor beta
  • Estrogens
  • Female
  • Humans
  • Lymphatic Metastasis
  • Neoplasm Proteins
  • Neoplasms, Hormone-Dependent
  • Prognosis
  • Survival Analysis
  • Comment
  • Editorial


Dive into the research topics of 'The evolving role of oestrogen receptor beta in clinical breast cancer'. Together they form a unique fingerprint.

Cite this